A detailed history of Swiss National Bank transactions in Merus N.V. stock. As of the latest transaction made, Swiss National Bank holds 85,654 shares of MRUS stock, worth $4.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
85,654
Previous 78,254 9.46%
Holding current value
$4.25 Million
Previous $4.63 Million 7.58%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$47.19 - $58.84 $349,206 - $435,416
7,400 Added 9.46%
85,654 $4.28 Million
Q2 2024

Aug 08, 2024

BUY
$39.81 - $60.2 $167,202 - $252,840
4,200 Added 5.67%
78,254 $4.63 Million
Q1 2024

May 07, 2024

BUY
$28.03 - $51.82 $39,242 - $72,548
1,400 Added 1.93%
74,054 $3.33 Million
Q4 2023

Feb 06, 2024

SELL
$20.06 - $28.66 $415,242 - $593,262
-20,700 Reduced 22.17%
72,654 $2 Million
Q3 2023

Nov 08, 2023

BUY
$20.13 - $27.29 $571,692 - $775,036
28,400 Added 43.72%
93,354 $2.2 Million
Q1 2023

May 10, 2023

SELL
$14.25 - $20.5 $99,750 - $143,500
-7,000 Reduced 9.73%
64,954 $1.2 Million
Q4 2022

Feb 08, 2023

BUY
$12.8 - $23.66 $61,440 - $113,568
4,800 Added 7.15%
71,954 $1.11 Million
Q3 2022

Nov 09, 2022

BUY
$18.64 - $28.93 $27,960 - $43,395
1,500 Added 2.28%
67,154 $1.35 Million
Q1 2022

May 09, 2022

BUY
$23.58 - $30.91 $108,467 - $142,186
4,600 Added 7.53%
65,654 $1.74 Million
Q4 2021

Feb 08, 2022

BUY
$20.0 - $32.29 $278,000 - $448,831
13,900 Added 29.48%
61,054 $1.94 Million
Q2 2021

Aug 06, 2021

SELL
$20.0 - $25.48 $66,000 - $84,084
-3,300 Reduced 6.54%
47,154 $994,000
Q1 2021

May 07, 2021

BUY
$16.14 - $29.11 $230,802 - $416,273
14,300 Added 39.55%
50,454 $1.05 Million
Q2 2020

Aug 05, 2020

BUY
$10.5 - $17.36 $379,617 - $627,633
36,154 New
36,154 $582,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.28B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.